MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q1
hinzugefügt 15.05.2023
Humanigen Operativer Cashflow 2011-2026 | HGEN
Operativer Cashflow Jährlich Humanigen
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -76.7 M | -184 M | -69.9 M | -4 M | -6.21 M | -14.2 M | -21 M | -29.1 M | -35.9 M | -38.8 M | -23.9 M | -15.3 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -4 M | -184 M | -43.3 M |
Operativer Cashflow Vierteljährlich Humanigen
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.06 M | - | -62.1 M | -44.8 M | -19.4 M | - | -152 M | -104 M | -35.8 M | - | -46.2 M | -22.6 M | -607 K | - | -3.45 M | -2.27 M | -684 K | - | -4.98 M | -3.73 M | -1.83 M | - | -12.3 M | -8.3 M | -4.36 M | - | -17.9 M | - | -2 M | - | -21.1 M | -14.9 M | -9.02 M | - | -29.1 M | -20.7 M | -11.3 M | - | -28.7 M | -20.4 M | -7.8 M | - | -15.3 M | -8.74 M | -3.45 M | - | -10.7 M | -10.1 M | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -607 K | -152 M | -21.9 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-19.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
5.96 B | - | - | $ 96.9 B | Britain |
 |
Avenue Therapeutics
ATXI
|
-1.83 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Axcella Health
AXLA
|
-69.6 M | - | -16.42 % | $ 249 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M |  Israel |
 |
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-235 M | - | - | $ 546 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
-4.34 M | - | -5.38 % | $ 6.06 M | USA |
 |
Atreca
BCEL
|
-80.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-26.8 M | - | - | $ 35.4 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
ChemoCentryx
CCXI
|
-75.6 M | - | - | $ 3.74 B | USA |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-17.8 M | - | -74.18 % | $ 955 K | USA |
 |
Chimerix
CMRX
|
-69.1 M | - | - | $ 756 M | USA |
 |
AbbVie
ABBV
|
19 B | $ 208.7 | -0.07 % | $ 369 B | USA |
 |
Calithera Biosciences
CALA
|
-66.3 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-23.5 M | - | -3.03 % | $ 260 M | USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 3.52 | -0.14 % | $ 1.05 B | Canada |